View More Recent Stories

Jul 6, 2016 01:00PM ABIVAX: Half-Year Report on the Liquidity Contract at 30 June 2016
Jun 17, 2016 12:00PM Analysis of Ongoing ABX203 Phase IIb/III Trial in Chronic Hepatitis B Virus Infection Shows Good Safety, but Primary Endpoint of Study is Unlikely to Be Reached
Jun 3, 2016 12:00PM ABIVAX: Combined Annual General Meeting: Availability of Supporting Documents
May 30, 2016 12:00PM Ongoing Clinical Development of ABX464: ABIVAX Launches ABX464-004 Study
May 9, 2016 12:00PM ABIVAX Publishes 2016 Shareholder Newsletter
Apr 27, 2016 12:00PM ABIVAX Abstract on ABX464 Selected for Presentation at the AIDS 2016 Conference in Durban, South Africa
Apr 25, 2016 12:00PM ABIVAX Enters into a Manufacturing Agreement with PCAS for ABX464, Thus Ensuring Drug Candidate Supply for Upcoming Clinical Trials
Apr 19, 2016 12:00PM ABIVAX Obtains Regulatory and Ethics Clearance in Spain to Begin Second Phase IIa Clinical Trial for ABX464 in HIV/AIDS Patients
Mar 31, 2016 12:00PM ABIVAX to Participate in the European Small-Cap Event in Paris on April 11-12, 2016
Mar 15, 2016 01:00PM ABIVAX: 2015 Full-Year Results and Progress Report
Feb 25, 2016 02:45PM ABIVAX’s Novel Approach to Treat HIV Demonstrates Safety and Preliminary Anti-viral Activity in Phase IIa
Feb 11, 2016 12:00PM ABIVAX To Participate in the Upcoming RBC Capital Markets 2016 Healthcare Conference in New York, and in the Credit Suisse Healthcare Conference in London
Jan 21, 2016 12:00PM ABIVAX to Present at the Prestigious Conference on Retroviruses and Opportunistic Infections (CROI) Positive Top-Line Clinical Phase IIa Data for Novel HIV Drug-Candidate ABX464
Jan 11, 2016 12:00PM ABIVAX announces positive top-line clinical Phase IIa data for novel HIV drug-candidate ABX464
Jan 8, 2016 12:30PM ABIVAX: Half-Year Report on the Liquidity Contract at 31 December 2015
Dec 21, 2015 12:00PM Abivax Completes Recruitment of ABX464 Phase IIa HIV Study
Dec 17, 2015 12:00PM ABIVAX to Present at the Biotech ShowcaseTM During the JP Morgan Healthcare Conference
Dec 10, 2015 12:00PM ABIVAX: 2016 Financial Calendar
Dec 8, 2015 12:00PM ABIVAX: ABX203 (HeberNasvac) Granted Cuban Marketing Authorization to Treat Chronic Hepatitis B
Nov 30, 2015 12:00PM ABIVAX Reports Healthy Volunteers Phase I Data for ABX464
Nov 24, 2015 12:00PM ABIVAX to Celebrate World AIDS Day with an Update on the Development of Its HIV Therapeutic Candidate, ABX464
Nov 12, 2015 01:04PM ABIVAX to Participate in the Upcoming Jefferies Global Healthcare Conference in London and the German Equity Forum in Frankfurt
Oct 15, 2015 12:00PM ABIVAX to Present at the BIO Europe 2015 Conference and at the Deutsches Eigenkapitalforum
Oct 1, 2015 12:00PM ABIVAX to Participate in the 15th Edition of the European Large & Midcap Event in Paris
Sep 29, 2015 12:41PM ABIVAX: Availability of the Half-Year Financial Report as of 30 June 2015
Sep 29, 2015 12:32PM ABIVAX – 2015 Half-Year Results
Sep 24, 2015 12:51PM ABIVAX Completes Recruitment in Its Phase IIb/III Pivotal Study with ABX203, First-in-Class Therapeutic Vaccine Against Chronic Hepatitis B
Sep 23, 2015 01:17PM ABIVAX Strengthens Its Senior Leadership Team by Appointing Dr. Jean-Marc Steens, M.D. as the Company’s Chief Medical Officer
View More Recent Stories